• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of General Medicine >Efficacy and safety of delapril/indapamide compared to different ACE-inhibitor/hydrochlorothiazide combinations: a meta-analysis
【24h】

Efficacy and safety of delapril/indapamide compared to different ACE-inhibitor/hydrochlorothiazide combinations: a meta-analysis

机译：与不同的ACE抑制剂/氢氯噻嗪组合相比，地拉普利/吲达帕胺的疗效和安全性：荟萃分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract: The main objective of this meta-analysis was to compare the efficacy of the combination of delapril and indapamide (D+I) to different angiotensin-converting enzyme inhibitor (ACEi) plus hydrochlorothiazide (HCTZ) combinations for the treatment of mild-to-moderate hypertension. A secondary objective was to examine the safety of these two combinations. Studies comparing the efficacy of D+I to ACEi+HCTZ combinations in hypertensive patients and published on computerized databases (1974–2010) were considered. Endpoints included percentage of normalized patients, of responders, change in diastolic and systolic blood pressure (DBP/SBP) at different time-points, percentage of adverse events (AEs), and percentage of withdrawal. Four head-to-head randomized controlled trials (D+I-treated, n = 643; ACEi+HCTZ-treated, n = 629) were included. Meta-analysis indicated that D+I-treated patients had a higher proportion with normalized blood pressure (P = 0.024) or responders (P = 0.002) compared to ACEi+HCTZ-treated patients. No difference was observed between treatments on absolute values of DBP and SBP at different time-points. Although the rate of patients reporting at least one AE was similar in both groups (10.4% versus 9.9%), events leading to study withdrawal were lower in the D+I group versus the ACEi+HCTZ group (2.3% versus 4.8%, respectively; P = 0.018). This meta-analysis suggests that treatment with D+I could provide a higher proportion of normalized or responder patients with good tolerability compared to ACEi+HCTZ combinations.
机译：摘要：这项荟萃分析的主要目的是比较地拉普利和吲达帕胺（D + I）组合对不同血管紧张素转化酶抑制剂（ACEi）加氢氯噻嗪（HCTZ）组合治疗轻度至中度的疗效。 -中度高血压。第二个目标是检查这两种组合的安全性。考虑了比较D + I与ACEi + HCTZ组合在高血压患者中的疗效的研究，该研究已发表在计算机数据库中（1974–2010）。终点包括正常患者，应答者的百分比，在不同时间点的舒张压和收缩压（DBP / SBP）的变化，不良事件（AE）的百分比以及戒断的百分比。包括四项头对头随机对照试验（D + I治疗，n = 643; ACEi + HCTZ治疗，n = 629）。荟萃分析表明，与ACEi + HCTZ治疗的患者相比，接受D + I治疗的患者血压正常化（P = 0.024）或有反应者（P = 0.002）的比例更高。在不同时间点，DBP和SBP绝对值的治疗之间未观察到差异。尽管两组中报告至少一种AE的患者发生率相似（10.4％对9.9％），但D + I组导致退出研究的事件要比ACEi + HCTZ组低（分别为2.3％对4.8％） ; P = 0.018）。这项荟萃分析表明，与ACEi + HCTZ组合相比，D + I治疗可以为更高比例的正常患者或应答患者提供良好的耐受性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号